A practical critique of antifungal treatment guidelines for haemato-oncologists.
The management of invasive fungal disease (IFD) in the haemato-oncology setting remains a challenge. This article reviews recent guidelines relating to IFD for their similarities and differences, as well as applying the Appraisal of Guidelines Research and Evaluation (AGREE) criteria. The guidelines' recommendations on antifungal prophylaxis, empirical and definitive treatment of candidiasis and aspergillosis are summarized; also, minimum standards for diagnosis and follow-up are discussed. This critique of the reviewed guidelines is a practical guide to physicians and commissioners in making local policies for IFD management.
Department of Haematological Oncology, St. Bartholomew's Hospital, (Blizard Institute, Queen Mary, University of London), London, UK. s.g.agrawal@qmul.ac.uk
Samir
S
Agrawal
Brian
B
Jones
Rosemary
R
Barnes
Chris
C
Kibbler
Mike
M
Millen
Mary
M
Ashcroft
Sarjana
S
Jain
Anna
A
Last
David
D
Lewis
Tom
T
Lewis
Mitul
M
Patel
Antonio
A
Pagliuca
D000935:Antifungal Agents / Q000627:therapeutic use*; D058365:Candidiasis, Invasive / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D018890:Chemoprevention / Q000379:methods; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D017410:Practice Guidelines as Topic
D000935:Antifungal Agents